For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
For laboratory research use only. Not for human consumption.
Talk to our research support team: 512-998-2437
Price range: $125.00 through $2,000.00
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Use Only
All research peptides supplied by OPTMZ Peptides are intended strictly for laboratory research applications and are not designed for medical use. These materials are not approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease. By purchasing, the buyer confirms use strictly for scientific research purposes and not for human or animal consumption.
Product Overview
GLP-3 R is a synthetic, lipidated research peptide investigated in controlled experimental environments for its activity across three metabolically relevant G-protein-coupled receptor systems: the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR).
This triple-receptor pharmacology distinguishes the compound from single-receptor GLP-1 agonists and dual GLP-1/GIP receptor agonists and has made the molecule an important experimental tool for investigating multi-receptor signaling, metabolic pathway integration, receptor pharmacology, and peptide structure-function relationships.
The lot-specific purity, measured content, identity, CAS number, and endotoxin result come directly from the Krause Analytical COA.
KEGG reports the reference molecule as a modified peptide with molecular formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight 4731.34, and targets GCGR, GIPR, and GLP1R.
Each tested batch of GLP-3 R undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory states that all values are reported on a per-vial basis unless otherwise noted.
The COA also contains the chromatogram on page 2, showing the dominant chromatographic peak for sample 205079, and the corresponding mass-spectral report on page 3.
GLP-3 R should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
GLP-3 R is investigated primarily as a triple receptor agonist involving GLP-1R, GIPR, and GCGR signaling.
Research areas include:
IUPHAR/BPS characterizes the reference compound as a lipidated peptide that activates all three receptors in vitro, with comparatively stronger binding/activity at GIPR.
These findings describe experimental research involving the reference molecule and do not establish therapeutic efficacy or intended use of the OPTMZ research material.
GLP-3 R is relevant to controlled experimental investigations involving simultaneous GLP-1R, GIPR, and GCGR signaling, multi-receptor pharmacology, metabolic pathway integration, receptor activation, and modified-peptide structure-function relationships.
The compound is particularly relevant for comparative experimental models examining the differences among single-, dual-, and triple-receptor agonism.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
The lot-specific purity, measured content, identity, CAS number, and endotoxin result come directly from the Krause Analytical COA.
KEGG reports the reference molecule as a modified peptide with molecular formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight 4731.34, and targets GCGR, GIPR, and GLP1R.
Each tested batch of GLP-3 R undergoes analytical evaluation to verify chromatographic purity, identity, peptide content, and analytical consistency.
For the submitted OPTMZ Peptides sample, Krause Analytical reported:
The laboratory states that all values are reported on a per-vial basis unless otherwise noted.
The COA also contains the chromatogram on page 2, showing the dominant chromatographic peak for sample 205079, and the corresponding mass-spectral report on page 3.
GLP-3 R should be handled by qualified professionals in controlled laboratory environments. Appropriate storage conditions should be maintained to preserve peptide stability and structural integrity.
Avoid unnecessary exposure to heat, moisture, light, and repeated temperature fluctuations. Experimental preparation, storage, and handling should follow validated laboratory procedures appropriate to the intended research application.
GLP-3 R is investigated primarily as a triple receptor agonist involving GLP-1R, GIPR, and GCGR signaling.
Research areas include:
IUPHAR/BPS characterizes the reference compound as a lipidated peptide that activates all three receptors in vitro, with comparatively stronger binding/activity at GIPR.
These findings describe experimental research involving the reference molecule and do not establish therapeutic efficacy or intended use of the OPTMZ research material.
GLP-3 R is relevant to controlled experimental investigations involving simultaneous GLP-1R, GIPR, and GCGR signaling, multi-receptor pharmacology, metabolic pathway integration, receptor activation, and modified-peptide structure-function relationships.
The compound is particularly relevant for comparative experimental models examining the differences among single-, dual-, and triple-receptor agonism.
For laboratory research use only. Intended strictly for in vitro and controlled experimental research applications.
All products currently listed on this site are for research purposes ONLY.
| Pcs | Single Vial, Pack of 10 |
|---|---|
| Strength | 10mg, 15mg, 30mg |
Triple Receptor Agonist / GLP-1R–GIPR–GCGR Agonist
Metabolic Research; Endocrinology; Peptide Biology; GPCR Pharmacology; Receptor Signaling; Molecular Pharmacology
GLP-1 Receptor (GLP-1R) / GIP Receptor (GIPR) / Glucagon Receptor (GCGR) All three are established molecular targets of the reference compound.
Clinical Research / Investigational The reference molecule has progressed into human clinical research, while remaining investigational. PubChem currently lists ongoing clinical investigation. This evidence classification refers to the scientific evidence surrounding the reference molecule and does not imply that the OPTMZ research product is an approved pharmaceutical product.
GLP-3 R is a synthetic 39-residue modified and lipidated peptide engineered for multi-receptor activity. Its structure incorporates noncanonical amino-acid modifications and a lipid-containing side chain. These modifications differentiate the molecule from naturally occurring GLP-1, GIP, and glucagon peptides and contribute to its distinctive triple-receptor pharmacology. IUPHAR/BPS describes the reference compound as a lipidated, modified peptide targeting GCGR, GIPR, and GLP-1R.
Modified 39-residue sequence: Y–Aib–QGTFTSDYSI–2-Me-Leu–LDK–[Lys(AEEA-γGlu-C20 diacid)]–AQAibAFIEYLLEGGPSSGAPPPS-NH₂ This is not a simple conventional amino-acid sequence because the molecule incorporates Aib residues, α-methyl-leucine, a modified lysine carrying a lipid-linked side chain, and a C-terminal serinamide. KEGG reports the 39-residue backbone and identifies the molecule as a modified peptide.
GLP-1R signaling studies
GIPR signaling studies
GCGR signaling studies
Triple-receptor activation studies
GPCR pharmacology
cAMP signaling research
Receptor potency comparisons
Multi-receptor pathway analysis
Metabolic signaling research
Insulin secretion models
Glucagon pathway research
Adipocyte biology
Energy-metabolism research
Lipidated-peptide structure-function studies
Single-vs-dual-vs-triple agonist comparisons
GLP-1R-expressing cell systems
GIPR-expressing cell systems
GCGR-expressing cell systems
Receptor-transfected cellular models
cAMP reporter systems
Pancreatic islet models
Adipocyte models
Hepatic metabolic models
Metabolic phenotyping systems
Receptor-binding models
Comparative incretin-receptor systems
Preclinical metabolic research models
HPLC-UV purity analysis
LC-MS identity analysis
Mass-spectral confirmation
USP endotoxin testing
GLP-1R activation assays
GIPR activation assays
GCGR activation assays
cAMP accumulation assays
Receptor-binding assays
Dose-response assays
Reporter-gene assays
Insulin secretion assays
Glucagon signaling assays
Cellular metabolic assays
For the actual OPTMZ lot, Krause Analytical specifically performed HPLC-UV-MS characterization and USP endotoxin testing.
Chromatographic purity
Peptide identity
Peptide content
Endotoxin concentration
GLP-1R activation
GIPR activation
GCGR activation
Intracellular cAMP
Receptor potency
Receptor efficacy
Insulin secretion
Glucagon-associated signaling
Cellular metabolic responses
Energy-metabolism endpoints
For the actual OPTMZ sample, directly measured analytical endpoints were chromatographic purity, identity, peptide content, and endotoxin concentration.
Independent analytical testing of OPTMZ Peptides GLP-3 R 15 mg, batch/lot 2026/02, by Krause Analytical reported:
Chromatographic Purity: >99.9%
Measured Content: 13.8 mg
Label Claim: 15 mg
Percent of Label: 92.0%
Identity: Confirmed by mass-spectral match
CAS Number: 2381089-83-2
Analysis Method: HPLC-UV-MS
Endotoxins: <0.5 EU/mL
Endotoxin Method: USP
Lab Number: 205079
Project: 145211
Batch/Lot: 2026/02
Date Received: April 28, 2026
Report Issued: May 8, 2026
The laboratory states that values are reported on a per-vial basis unless otherwise noted.
Restricted Access · Research Use Only
Independently lab tested, every batch
COAs published and searchable by batch number
Policy version 2026-05-14-ruo-v1.0
Reviews
There are no reviews yet.